Abstract
CD200 is a transmembrane molecule with an important immunoregulatory role that is overexpressed on most chronic lymphocytic leukemia (CLL) cells. In this study, we characterized a previously unknown soluble form of this molecule in human plasma termed sCD200. Levels of sCD200 were elevated in the plasma of patients with CLL as compared with healthy controls, and there was a significant correlation with CLL disease stage. Infusion of sCD200(hi) CLL plasma into severely immunocompromised NOD.SCIDγ(c)(null) (NSG) mice enhanced the engraftment of CLL splenocytes as compared with mice receiving sCD200(lo) normal plasma. CLL cells were detected in both the spleen and peritoneal cavity of animals for up to 75 days. Engraftment of CLL cells did not occur after infusion of CLL plasma depleted of sCD200 and was abolished in mice treated with anti-CD200 or OKT3 monoclonal antibody (mAb), suggesting a role for both sCD200 and T cells in CLL engraftment. Notably, anti-CD200 mAb was as effective as rituximab in eliminating engrafted CLL cells when administered 21 days after engraftment. Taken together, our findings point to sCD200 as a novel prognostic marker and therapeutic target for CLL. Furthermore, the humanized mouse model described here may prove valuable to preclinically assess new treatment regimens for CLL.
Highlights
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease characterized by the accumulation of malignantCD5þCD19þ B cells in peripheral blood, bone marrow, and secondary lymphoid organs
We have previously shown that CD200, an immunoregulatory molecule overexpressed on a number of solid and systemic tumors, as well as cancer stem cells, played a functional role in suppressing cytotoxic killing of CD200þ lymphoma and CLL
We investigated whether soluble form of CD200 (sCD200) present in patients with CLL plasma might contribute to growth/survival of CLL cells in NOD.SCIDg cnull (NSG)
Summary
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease characterized by the accumulation of malignantCD5þCD19þ B cells in peripheral blood, bone marrow, and secondary lymphoid organs. Improved understanding of the biology of CLL may help identify other variables predicting which patients may have a poor disease outcome. We have previously shown that CD200, an immunoregulatory molecule overexpressed on a number of solid and systemic tumors, as well as cancer stem cells, played a functional role in suppressing cytotoxic killing of CD200þ lymphoma and CLL cells [1,2,3,4,5,6]. Increased expression of CD200R, which is required for signaling mediated following CD200 engagement, was detected on a subpopulation of CD4þ T cells in the spleen of patients with CLL relative to controls [6]. CD200þ CLL cells and CD200Rþ CD4þ T cells seem to colocalize in the tumor microenvironment
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
